205194-33-8

Basic information

• Product Name: 4-(3-HYDROXYPROPYL)THIOMORPHOLINE 1,1-DIOXIDE
• Synonyms: 4-(3-HYDROXYPROPYL)THIOMORPHOLINE 1,1-DIOXIDE;3-(1,1-DIOXOTHIOMORPHOLINO)-1-PROPANOL;N-(3-HYDROXYPROPYL)THIOMORPHOLINE 1,1-DIOXIDE;N-(3-DYDROXYPROPYL)THIOMORPHOLINE 1,1-DIXOXIDE;N-(3-DYDROXYPROPYL)THIOMORPHOLINE-1,1-DIOXIDE
• CAS NO: 205194-33-8
• Molecular Formula: C₇H₁₅NO₃S
• Molecular Weight: 193.26
• Mol File: 205194-33-8.mol
• Article Data: 8

Chemical Properties

• Melting Point: 70.0 to 74.0 °C
• Boiling Point: 418.25°C at 760 mmHg
• Flash Point: 206.751°C
• Appearance: /
• Density: 1.241g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.511
• Solubility: soluble in Methanol
• CAS DataBase Reference: 4-(3-HYDROXYPROPYL)THIOMORPHOLINE 1,1-DIOXIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-HYDROXYPROPYL)THIOMORPHOLINE 1,1-DIOXIDE(205194-33-8)
• EPA Substance Registry System: 4-(3-HYDROXYPROPYL)THIOMORPHOLINE 1,1-DIOXIDE(205194-33-8)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 205194-33-8(Hazardous Substances Data)

Usage

General Description

4-(3-Hydroxypropyl)thiomorpholine 1,1-dioxide, also known as Lesdiox, is a registered fungicide used for controlling various diseases in crops. It is a mono-classified product bearing potential risks of genotoxicity. This chemical works effectively on certain types of fungi that can cause diseases in many types of vegetables, fruits, and cereal crops. Like all fungicides, it should be used with caution. Although it's not highly toxic, prolonged exposure can cause irritations, allergies and other more serious health problems. Its chemical formula is C7H15NO4S and it appears as a white crystalline powder. The chemical belongs to the class of organic compounds known as morpholines, which contain a saturated aliphatic ring.

InChI:InChI=1/C7H15NO3S/c9-5-1-2-8-3-6-12(10,11)7-4-8/h9H,1-7H2

Upstream product

• 77-77-0 Divinyl sulfone 
• 156-87-6 propan-1-ol-3-amine 

Downstream Products

• 288386-86-7 3-(1,1-dioxothiomorpholino)-1-propanoltosylate 
• 1221413-89-3 4-(3-thiomorpholine-1,1-dioxidepropoxy)benzaldehyde 
• 1392311-71-5 4-[(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-[[[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]carbonyl]amino]-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-5a,5b,8,8,11a-pentamethyl-1-(1-methylethenyl)-1H-cyclopenta[a]chrysen-9-yl] mono-trifluoroacetic acid 
• 1392315-19-3 methyl 4-[(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-[[2-(1,1-dioxido-4-thiomorpholinyl)propyl]amino]-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-5a,5b,8,8,11a-pentamethyl-1-(1-methylethenyl)-1Hcyclopenta[a]chrysen-9-yl]-2-fluoro-benzoate 

Relevant articles and documents

Quinazoline derivatives

The invention concerns quinazoline derivatives of Formula (I) wherein Q1includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3—X1— wherein X1includes a direct bond and O and Q3includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R2and R3is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q2includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.

Quinazoline derivatives

The invention concerns quinazoline derivatives of Formula (I) wherein each of m, R1, n, R2 and R3 have any of the meanings defined in the description; process for the preparation, pharmaceutical compositions them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

Cinnoline compounds

The invention relatest to compounds of the formula (I) wherein either any one of G1, G2, G3, G4 and G5 is nitrogen and the other four are —CH—, or G1, G2, G3, G4 and G5 are all —CH—; Z is —O—, —NH—, —S—, —CH2— or a direct bond; Z is linked to any one of G1, G2, G3 and G4 which is a free carbon atom; n is an integer from 0 to 5; any of the substitutents R1 may be attached at any free carbon atom of the indole, azaindole or indazole group; m is an integer from 0 to 3; Ra represents hydrogen; Rb represents hydrogen or another value as defined herein; R1 represents hydrogen, oxo, hydroxy, halogeno, C1-4alkyl, C1-4alkoxy, C1-4alkoxy, C1-4-alkyl, aminoC1-4alkyl, C1-3alkylaminoC1-4alkyl, di(C1-3alkyl)aminoC1-4alkyl, —C1-5alkyl(ring B) wherein ring B is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-methylpiperazinly, N-ethylpiperazinyl, morpholino and thiomorpholino; R2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3aklylsulphanyl, —NR3R4 (wherein R3 and R4, which may be the same or different, each represents hydrogen or C1-3alkyl), or R5X1— (wherein R5 and X1 are as defined herein) and salts thereof, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of a compound of formula I in the manufacture of medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.